Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

BACKGROUND: Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed pooled safety results from three phase 3 IV golimumab trials in these rheumatologic diseases and hypothesized that the safety pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Husni, M. Elaine, Deodhar, Atul, Schwartzman, Sergio, Chakravarty, Soumya D., Hsia, Elizabeth C., Leu, Jocelyn H., Zhou, Yiying, Lo, Kim H., Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935699/
https://www.ncbi.nlm.nih.gov/pubmed/35313978
http://dx.doi.org/10.1186/s13075-022-02753-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935699/
https://www.ncbi.nlm.nih.gov/pubmed/35313978
http://dx.doi.org/10.1186/s13075-022-02753-6

Ejemplares similares